Seres Therapeutics, Inc. (1S90)

Overview

Seres Therapeutics, Inc. is a pioneer in the rapidly evolving sector of microbiome therapeutics, which focuses on employing the natural flora found in the human gut to treat a variety of diseases. Standing at the forefront of this innovative field, the company develops a new class of biological drugs aimed at modulating the microbiome to reinstate health by amending the functions of a disrupted microbiome back to a non-diseased state. Originally founded as Seres Health, Inc., the organization underwent a rebranding to Seres Therapeutics, Inc. in May 2015, marking a significant milestone in its commitment to transforming the approach towards treating diseases through microbiome technology. Based in Cambridge, Massachusetts, and established in 2010, Seres Therapeutics, Inc. has cemented its place as a leading entity focused on unlocking the potential of the human microbiome to address unmet medical needs.

Products and Services

• VOWST

  An oral microbiome therapeutic and the leading product candidate of Seres Therapeutics, Inc., VOWST has reached the completion of Phase III clinical trials. Its primary application is towards the treatment of recurrent Clostridioides difficile infection (CDI), showcasing the company’s expertise in leveraging microbiome therapeutics to combat persistent infections.

• SER-155

  This investigational oral fermented microbiome therapeutic is currently in Phase 1b clinical trials. SER-155 is formulated to prevent gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised individuals, including those undergoing allogeneic hematopoietic stem cell transplantation. This further echoes the company's focus on creating solutions for critical and complex medical conditions through innovative microbiome technology.

• SER-287 and SER-301

  Both products are part of Seres Therapeutics’ ambitious pipeline aimed at addressing ulcerative colitis. SER-287 is advancing through Phase 2b clinical trials, whereas SER-301 is currently undergoing Phase 1b trials. These developments reflect the company’s dedication to expanding its portfolio to include treatments for inflammatory bowel diseases, utilizing the therapeutic potentials of microbiome modulation.

• Collaboration and Licensing Agreements

  Seres Therapeutics has entered into a license agreement with NHSc Rx License GmbH concerning their microbiome technology. This agreement includes the development of the VOWST product candidate for treating CDI and recurrent CDI. Additionally, the company boasts a collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé), aiming at the development and commercialization of certain product candidates focusing on the treatment and management of CDI and inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. These alliances underline Seres Therapeutics’ strategy to partner with leading global entities to broaden the reach and impact of its microbiome-based therapeutic solutions.